Tuberculosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Tuberculosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

February 28
05:09 2023
Tuberculosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Tuberculosis pipeline constitutes 35+ key companies continuously working towards developing 25+ Tuberculosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Tuberculosis Overview

Tuberculosis (TB) is an ancient human disease caused by Mycobacterium tuberculosis which mainly affects the lungs making pulmonary disease the most common presentation. The organ system most commonly affected includes the respiratory system, the gastrointestinal (GI) system, the lymphoreticular system, the skin, the central nervous system, the musculoskeletal system, the reproductive system, and the liver. Tuberculosis is curable and preventable.

 

Tuberculosis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tuberculosis Market.

 

The Tuberculosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Tuberculosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Tuberculosis treatment therapies with a considerable amount of success over the years. Tuberculosis Key players such as – PDS Biotechnoloy, BioNTech, GlaxoSmithKline, TB Alliance, Sequella, GlaxoSmithKline, Archivel Farma, GC Biopharma, Zhifei Longcom, Biofabri, and others, are developing therapies for the Tuberculosis treatment 
  • Tuberculosis Emerging therapies such as – PDS0201, BNT164, GSK2556286, TBAJ-876, Sutezolid, GSK3036656, RUTI, GC3107A, AEC/BCO2, MTBVAC, and others are expected to have a significant impact on the Tuberculosis market in the coming years.   
  • In March 2022, Bharat Biotech entered into a partnership with Biofabri for the development, manufacturing and marketing of a new Tuberculosis Vaccines. Bharat Biotech has opted for this vaccine candidate owing to its advanced stage of clinical development as well as the promising results from Phase-I and Phase-II clinical trials.
  • In July 2022, Biofabri initiated a Phase III randomized, double-blind, controlled trial to evaluate the efficacy, safety and immunogenicity of MTBVAC in healthy HIV unexposed and HIV expose duninfected newborns in Tuberculosis-Endemic regions of Sub-Saharan Africa.

 

Route of Administration

Tuberculosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Tuberculosis Pipeline Therapeutics Assessment

  • Tuberculosis Assessment by Product Type
  • Tuberculosis By Stage and Product Type
  • Tuberculosis Assessment by Route of Administration
  • Tuberculosis By Stage and Route of Administration
  • Tuberculosis Assessment by Molecule Type
  • Tuberculosis by Stage and Molecule Type

 

DelveInsight’s Tuberculosis Report covers around 5+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Tuberculosis Therapeutics Market include:

Key companies developing therapies for Tuberculosis are – Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Qurient Co., Sequella, Inc., Vaxil Biotherapeutics, Tianjin CanSino Biotechnology, Global Alliance for TB Drug Development, BioNtech, TaBriX, Moderna, GC Biopharma, AJ Vaccines, Vaxxit Srl, Vaxil Bio Therapeutics, Vaxine Pty Ltd,  TVAX Biomedical, Theravectys SA, Tydockpharma, PDS Biotechnology, PAI lifesciences, EpiVax, Inc., GlobeImmune Inc., Zymergen, Jiangsu Recbio Technology, and others.

 

Emerging Tuberculosis Drugs Under Different Phases of Clinical Development Include:

  • PDS0201: PDS Biotechnoloy
  • BNT164: BioNTech
  • GSK2556286: GlaxoSmithKline
  • TBAJ-876: TB Alliance
  • Sutezolid: Sequella
  • GSK3036656: GlaxoSmithKline
  • RUTI: Archivel Farma
  • GC3107A: GC Biopharma
  • AEC/BCO2: Zhifei Longcom
  • MTBVAC: Biofabri

 

Get a Free Sample PDF Report to know more about Tuberculosis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight

 

Tuberculosis Pipeline Analysis:

The Tuberculosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Tuberculosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tuberculosis Treatment.
  • Tuberculosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Tuberculosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tuberculosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Tuberculosis product details are provided in the report. Download the Tuberculosis pipeline report to learn more about the emerging Tuberculosis therapies

 

Tuberculosis Pipeline Market Drivers

  • Increasing R&D Investments and new drug developments

 

Tuberculosis Pipeline Market Barriers

  • High pricing of drugs specially second line treatment

 

Scope of Tuberculosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Tuberculosis Companies: PDS Biotechnoloy, BioNTech, GlaxoSmithKline, TB Alliance, Sequella, GlaxoSmithKline, Archivel Farma, GC Biopharma, Zhifei Longcom, Biofabri, and others
  • Key Tuberculosis Therapies: PDS0201, BNT164, GSK2556286, TBAJ-876, Sutezolid, GSK3036656, RUTI, GC3107A, AEC/BCO2, MTBVAC, and others
  • Tuberculosis Therapeutic Assessment: Tuberculosis current marketed and Tuberculosis emerging therapies
  • Tuberculosis Market Dynamics: Tuberculosis market drivers and Tuberculosis market barriers 

 

Request for Sample PDF Report for Tuberculosis Pipeline Assessment and clinical trials

 

Table of Contents

1

Tuberculosis Report Introduction

2

Tuberculosis Executive Summary

3

Tuberculosis Overview

4

Tuberculosis- Analytical Perspective In-depth Commercial Assessment

5

Tuberculosis Pipeline Therapeutics

6

Tuberculosis Late Stage Products (Phase II/III)

7

Tuberculosis Mid Stage Products (Phase II)

8

Tuberculosis Early Stage Products (Phase I)

9

Tuberculosis Preclinical Stage Products

10

Tuberculosis Therapeutics Assessment

11

Tuberculosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Tuberculosis Key Companies

14

Tuberculosis Key Products

15

Tuberculosis Unmet Needs

16 

Tuberculosis Market Drivers and Barriers

17

Tuberculosis Future Perspectives and Conclusion

18

Tuberculosis Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Tuberculosis drugs and therapies

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Categories